Target intelligence / Profile preview

Alpha-ketoglutarate dehydrogenase subunit 4 (KGD4)

Target
KGD4
Molecular classification
Enzyme (subunit of the alpha-ketoglutarate dehydrogenase complex), Other (historically misclassified as a ribosomal protein, but evidence supports its primary role in the enzyme complex)
01

Overview

Alpha-ketoglutarate dehydrogenase subunit 4 (KGD4) is an evolutionarily conserved structural subunit of the mitochondrial alpha-ketoglutarate dehydrogenase enzyme complex, crucial for the citric acid cycle and energy production in eukaryotic cells. KGD4 acts as a molecular adaptor that links the E1-E2 catalytic core to the E3 subunit, stabilizing the assembled complex and ensuring efficient enzymatic activity. Originally annotated as a mitochondrial ribosomal protein (MRPS36), further research has shown that KGD4 does not contribute to ribosomal function but rather plays a vital role in the organization and stability of the dehydrogenase complex. Defects in KGD4 are associated with mitochondrial diseases such as Leigh disease and may have broader implications in aging, neurodegeneration, and cancer due to its impact on cellular energy metabolism and mitochondrial function.

Other names
Alpha-ketoglutarate dehydrogenase component 4MRPS36DC47MRP-S3628S ribosomal protein S36, mitochondrialS36mtmitochondrial ribosomal protein S36
02

Mechanism of action

Not applicable (no current drugs directly target KGD4). For the alpha-ketoglutarate dehydrogenase complex: inhibition by metabolic poisons (e.g., arsenite), but these act on the enzyme complex rather than specifically on KGD4.

03

Biological functions

Organization and stability of the mitochondrial alpha-ketoglutarate dehydrogenase complexRecruitment of E3 subunit to the enzyme, acting as a molecular adaptor essential for complex formation and functionCellular energy metabolism, specifically in the citric acid (Krebs) cycleMitochondrial function
04

Disease associations

Leigh diseasePotential involvement in neurodegenerative diseasesPossible roles in cancer and aging through mitochondrial dysfunction
05

Safety considerations

As part of the mitochondrial alpha-ketoglutarate dehydrogenase complex, impairment may lead to mitochondrial dysfunction, resulting in lactic acidosis and progressive neurological disorders such as Leigh diseaseNo specific therapeutic safety concerns for drugs directly targeting KGD4
06

Biomarkers

None specific to KGD4 identified; decreased activity of the alpha-ketoglutarate dehydrogenase complex can indicate mitochondrial dysfunction in diseases such as Leigh disease

Beyond the preview

Go deeper on Alpha-ketoglutarate dehydrogenase subunit 4 (KGD4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-ketoglutarate dehydrogenase subunit 4 (KGD4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call